← FDA DRUG APPROVALS

FDA ANDA · ANDA207466

METAXALONE

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA207466
TYPE
ANDA
ORIGINAL APPROVAL
2017-08-31
LATEST ACTION
2025-03-21
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

METAXALONEPrescription
METAXALONE 800MG · TABLET · ORAL
METAXALONEPrescription
METAXALONE 400MG · TABLET · ORAL

Approval history

2025-03-21Labeling · Supplement 17 · standardAP
2019-09-27Labeling · Supplement 5 · standardAP
2017-08-31UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →